SCHEMBL1337693

SCHEMBL1337693

COc1ccc(Cl)c(-c2cc(F)c(NC(=O)c3ccccc3C(=O)O)c(F)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 9/20 0.50
KMT2A Q03164 5/20 0.46
MEN1 O00255 2/20 0.46
DDX3X O00571 1/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 1/20 0.45
PYGL P06737 1/20 0.44
PYGM P11217 1/20 0.44
GAA P10253 2/20 0.43
KDM4E B2RXH2 1/20 0.43
POLB P06746 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1336603 0.96 DHODH (0.46) DHODHKMT2AMEN1DDX3XNPC1
SCHEMBL1337587 0.90 DHODH (0.53) DHODHKMT2AMEN1DDX3XNPC1
SCHEMBL1335675 0.89 DHODH (0.46) DHODHKMT2AMEN1DDX3XNPC1
SCHEMBL1336906 0.84 DHODH (0.67) DHODHKMT2AMEN1NPC1RAB9A
SCHEMBL1337841 0.82 DHODH (0.51) DHODHKMT2AMEN1DDX3XNPC1
SCHEMBL1337760 0.82 DHODH (0.67) DHODHNPC1RAB9AGAAKDM4E
SCHEMBL1337620 0.82 NPC1 (0.52) DHODHKMT2AMEN1NPC1RAB9A
SCHEMBL1337648 0.81 KDM4E (0.51) DHODHKMT2AMEN1NPC1RAB9A
SCHEMBL1337800 0.80 DHODH (0.53) DHODHKMT2ADDX3XNPC1RAB9A
SCHEMBL1335392 0.80 DHODH (0.46) DHODHKMT2ADDX3XNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 EP claimed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US claimed
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 EP disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR DHODH 1/4885KMT2A 2931/4885MEN1 4837/4885
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR DHODH 1/4885KMT2A 2931/4885MEN1 4837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.